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Abstract
Alcohol-associated memories and craving play a crucial role in the development and maintenance of alcohol use
disorder (AUD). As treatment options are limited in AUD, novel treatment strategies focus on the manipulation of
alcohol-associated memories. The stress hormone cortisol affects various memory processes, and first clinical studies
have shown that it inhibits the retrieval of disorder-specific memories and enhances extinction memory. This study
aimed to investigate the effects of a single oral administration of cortisol on craving in patients with AUD during
repeated in vivo exposure to alcohol pictures and the preferred alcoholic drink. In a double-blind, block-randomized,
placebo-controlled cross-over design, 46 patients with AUD were treated with two sessions of in vivo exposure to
alcohol. Cortisol (20 mg) or placebo was orally administered 1 h before each test day. Craving, stress, and cortisol were
repeatedly measured during exposure sessions. Results show, that cortisol administration had distinct effects on
craving depending on the severity of AUD and test day. While cortisol administration significantly enhanced craving
during exposure on the first test day in patients with less severe AUD, it reduced craving in patients with more severe
AUD. Independent of the cortisol administration, repeated in vivo exposure reduced craving from test day 1 to test
day 2. In conclusion, adding cortisol to in vivo exposure might be a promising approach for reducing the strength of
alcohol-associated memories and might promote the consolidation of extinction memory in patients with severe
AUD. However, the differential effect of cortisol on craving depending on AUD severity cannot be conclusively
explained and highlights the need for future studies elucidating the underlying mechanism.
Introduction
Alcohol use disorder (AUD) is a severe chronic illness
with a multifactorial etiology1, characterized by high rates
of relapse even after intensive residential treatment2.
Despite significant progress in the development of effi-
cacious psychological and pharmacological treatments for
AUD, 1-year relapse rates remain with more than 50%
very high3 and the prognosis regarding drinking outcome
deteriorates significantly with each additional detoxifica-
tion treatment4,5. Strong memories about cues (e.g.,
people, places, things, emotions) that are repeatedly
associated with alcohol use can promote craving and
compulsive alcohol taking and are a primary trigger of
relapse6,7. With increasing duration and severity of AUD,
these cues may also initiate the subconscious habitual and
compulsive behaviors associated with obtaining and tak-
ing alcohol that further increases the likelihood of a full-
blown relapse8. Therefore, learning and memory pro-
cesses such as acquisition, consolidation, and retrieval
play a crucial role in the development and maintenance of
AUD. Accordingly, new treatment approaches have
focused on the manipulations of learning and memory
processes, including extinction and reconsolidation pro-
cesses, to either strengthen or weaken the memory6.
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In the context of exposure-based therapy, the process of
extinction is of particular interest. Repeated or prolonged
exposure to cues in the absence of alcohol ingestion can
lead to the formation of a new “extinction” memory. Like
other forms of learning, extinction acquisition is followed
by a consolidation phase of the extinction memory where
a cue is not associated with alcohol use anymore6,9. Even
though there is some evidence from clinical studies that
cue extinction approaches, such as exposure techniques in
cognitive behavioral therapy, can reduce some of the
conditioned physiological effects induced by drug cues
and reduces subjective levels of craving10,11, many of the
patients do not respond to treatment, or achieve only
partial remission of symptoms12. Consequently, more
recent research has focused on pharmacological manip-
ulations that might be used in conjunction with extinction
to help individuals to reduce relapse and maintain absti-
nence. Thus, drugs with the potential to enhance
extinction like glucocorticoids (cortisol in humans)13–16
might be promising candidates to enhance exposure
therapy and reduce alcohol-taking behavior.
Glucocorticoids are stress hormones released from the
adrenal cortex that affect various memory processes.
Despite the growing body of research on the effects of
stress and glucocorticoids on memory processes, there are
a number of inconsistencies indicating that such effects
depend on many factors, such as the memory phase under
study, time and dose of intervention, level of emotional
arousal or gender17–24. Studies in animals and humans
have shown that glucocorticoids inhibit memory retrieval
while at the same time they enhance the consolidation of
new memories and facilitate memory extinction pro-
cesses13,14,25–28. Emotionally arousing information has
been shown to be especially sensitive to this glucocorti-
coid effects26, which was the basis for several clinical
studies investigating whether glucocorticoids can reduce
the retrieval of aversive disorder-specific memories in
patients with different psychiatric disorders. The acute
administration of glucocorticoids reduced aversive
disorder-specific memory retrieval, which was shown in
reduced fear symptoms in patients with anxiety dis-
orders14, reduced intrusions in chronic post-traumatic
stress disorder29 and reduced craving in heroin-
dependent patients30 during exposure. In addition, the
conjunction of endogenously or exogenously elevated
glucocorticoid levels and exposure-based therapy pro-
moted the consolidation of fear extinction in patients with
anxiety disorders13,15,31. Whereas the majority of rando-
mized clinical trials have shown beneficial effects in PTSD
and phobias, it has to be noted that the evidence comes
from rather small proof‑of‑concept studies and there have
been reports with weak or absent effects19.
Disorder-specific memories play a crucial role in the
development and maintenance of various psychiatric
disorders. In AUD, the confrontation with an alcohol-
related stimulus invariably provokes the retrieval of
associated alcohol-related memories that might lead to
increased craving and urge to drink. Therefore, the
administration of glucocorticoids could result in reduced
retrieval of addiction memory and, thereby, reduce feel-
ings of craving.
In the present randomized placebo-controlled double-
blind cross-over study we examined the effects of the
acute administration of glucocorticoids on craving in
patients with AUD attending a cue exposure treatment
session. We expect that patients receiving cortisol prior to




Detoxified patients with AUD attending a twelve-week
abstinence-oriented residential treatment program for
AUD in a specialized treatment center (Clinic Suedhang)
were asked to participate in the study. Forty-eight patients
with AUD according to ICD-10 gave written informed
consent to participate in this randomized placebo-
controlled double-blind cross-over study. A sample size
of 44 patients was estimated on the basis of the assump-
tion of a medium effect size of d= 0.5 at an alpha level of
0.05 and a power of 0.9. Inclusion criteria consisted of an
age older than 18, abstinent from alcohol for at least
6 weeks, and attending the 12-week abstinent-oriented
inpatient treatment program at the clinic Suedhang. Cri-
teria for exclusion were severe comorbid psychiatric dis-
orders (e.g., major depression or schizophrenia), current
medical conditions excluding participation (such as acute
infectious disease), recent history of systemic or topic
glucocorticoid therapy, known hypersensitivity to the
investigational medicinal product (IMP) (cortisol), preg-
nancy, breast-feeding, inability to read and understand the
participant’s information, positive alcohol test according
to breathalyser. Two patients had to be excluded because
of the following reasons: one due to cognitive impairment,
which resulted in incomplete and erroneous processing of
the questionnaires, the other one due to extreme baseline
values on test day 2 in craving, which might have been
caused by negative events experienced between the test
days. The final sample consisted of 46 patients (12
females, 34 males) with an average age was 45.3 years (SD
11.32) and an average duration of problematic alcohol
consumption of 11.9 years (SD 9.97). Detailed sample
description is shown in Table 1. The local ethic com-
mittee and the Swiss agency for the authorization and
supervision of therapeutic products (Swissmedic, Bern,
Switzerland) approved the study (Nr: 068/2014; SNCPT
207). The study was registered with ClinicalTrials.gov (Nr:
NCT02196142) and monitored by the Clinical Trial Unit
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(CTU) of the University of Bern. The blinding was
maintained throughout the study. All participants
received 80 Swiss francs as a compensation for their
participation.
Procedure and measurements
The study took place on 2 study days (120 min duration
each) between 1 pm and 4 pm at the Clinic Suedhag,
Kirchlindach, Switzerland between November 2014 and
June 2015. The 2 study days had the exact same procedure
and were one week apart from each other (see Fig. 1). The
study consisted of a pre-test assessment consisted of a
pre-test screening consisting of an interview to clarify
study eligibility and patients were asked to fill out several
questionnaires to assess symptom severity. Test day 1 and
2 took place between week 6 and 8 of the patients’ resi-
dential treatment program and consisted of a standar-
dized exposure procedure to neutral and alcohol pictures
followed by a in vivo exposure to the preferred alcoholic
drink. Each test day started with a breathalyser test to
control for alcohol intake and a pregnancy test before the
first saliva sample was collected and psychometric mea-
sures with the study test battery were assessed (see Fig. 1).
After the oral administration of either 20mg of hydro-
cortisone or placebo a resting period of 1 h followed
allowing the absorption of the study medication. After the
resting time period patients were presented for 10 min
with neutral photographs (5 min) taken from the inter-
national affective picture system (IAPS; University of
Florida, NIMH Center for the Study of Emotion and
Attention, Gainsville, Fl) and alcohol photographs (5 min)
on a computer. Immediately following the presentation of
the neutral and alcohol photograph block, patients were
asked to rate the pictures for valence, arousal, and craving
using Visual Analog Scales (VAS). A standardized in vivo
exposure task, consisting of the confrontation to the
preferred alcoholic drink followed. The in vivo exposure
task consisted of three consecutive phases: (i) looking at
the preferred alcoholic drink in the bottle; (ii) opening the
bottle and pouring it in a glass; (iii) holding the glass and
smelling at the alcoholic drink. Again, patients were asked
to rate each phase for craving and stress using VAS
Table 1 Demographic, baseline, and clinical variables of interest.
All (N= 46) Cortisol-Placebo-Group (N= 23) Placebo-Cortisol-Group (N= 23) P-values
Females/males 12/34 7/16 5/18 0.502
Oral contraceptives yes/no 3/9 2/5 1/4 0.733
Age 44.83 (11.31) 42.61 (10.79) 47.06 (11.60) 0.185
Years of probl. drinking 11.33 (9.49) 10.17 (7.65) 12.48 (11.09) 0.417
Nr. of detoxifications 2.43 (3.12) 3.00 (4.10) 1.87 (1.55) 0.223
Group: 1 detox./2+ detox. 21/25 10/13 11/12 0.767
Days of abstinence 51.09 (24.79) 53.43 (27.35) 48.74 (22.31) 0.527
AUDIT 25.33 (4.91) 25.64 (4.26) 25.04 (4.26) 0.690
AASE 63.18 (18.88) 61.59 (18.53) 64.77 (19.52) 0.582
BSCL GSI 4.66 (0.34) 0.55 (0.37)G 0.386 (0.31) 0.114
BDI-II 8.35 (5.85) 8.35 (5.85) 7.78 (4.90) 0.519
BMI 25.61 (3.85) 26.35 (4.05) 24.87 (4.05) 0.217
AUC G Placebo 16124.13 (8859.77)
AUC G Cortisol 78239.9 (93125.07)
OCDS T1_1 20.0 (9.14) 20.30 (7.90) 19.70 (10.41) 0.824
OCDS T2_1 8.35 (5.85) 16.13 (7.57) 13.82 (6.94) 0.268
STAI-State T1_1 35.78 (7.76) 37.13 (8.44) 34.43 (6.94) 0.243
STAI-State T2_1 23.89 (4.13) 34.48 (8.25) 31.61 (5.02) 0.162
AUQ T1 9.61 (2.71) 9.61 (2.78) 9.61 (2.71) 1.00
AUQ T2 9.04 (2.19) 8.87 (1.96) 9.22 (2.43) 0.596
Note: Group 1 Detox: Patient group with one previous detoxification; Group 2+ Detox: Patient group with two or more previous detoxifications; years of probl.
drinking: years of problematic drinking; AUDIT: Alcohol Use Disorders Identification Test; OCDS: Obessive-compulsive drinking scale; T1: exposure session 1; T2:
exposure session 2; BDI-II: Beck depression inventory; STAI-State: Spielberger State Anxiety Inventory; BSCL GSI: Global severity index of the Brief Symptom Check List;
AASE: alcohol abstinence self-efficacy scale; BMI: body mass index; AUC: area under the curve; CAR: cortisol awakening response; AUQ: alcohol urge questionnaire.
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between the different exposure components (Fig. 1). At
the end of each test day participants were interviewed
regarding their current wellbeing and asked whether they
think they received cortisol or placebo.
Study medication, randomization, and blinding
The participants were allocated randomly by the time of
study entry to receive either oral cortisol (20 mg, two
tablets each of 10 mg of hydrocortisone; Galepharm,
Küsnacht, Switzerland) or placebo (two similar-looking
tablets; Galepharm Küsnacht, Switzerland) at the first
testing day. Due to the overencapsulation of the medica-
tion and the administration of just one capsule at visit 1
and one further capsule at visit 2, patients were not able to
detect differences between the study medications (cross-
over design). This dose of cortisol has been used in pre-
vious studies investigating the effects of a single admin-
istration of cortisol on phobic fear14,15 and craving in
patients with heroin addiction30. After a washout period
of 7 days, participants received on the second testing day
the treatment (cortisol or placebo) that they had not
received on the first testing day. The preparation of study
medication and blinding was performed by the Pharmacy
of the University Hospital Bern according to Good Clin-
ical Practice (GCP). Randomization was stratified in a
counterbalanced way according to order of medication
(i.e., either IMP or placebo first). The IMP and the pla-
cebo were encapsulated in identically looking capsules. At
testing day 1 eligible patients were allocated to the
treatment group (i.e., either IMP or placebo first) fol-
lowing the order of the randomization list. The rando-
mization number was listed in the CRF.
Saliva cortisol measurement
Four saliva samples were collected using the Salivette
(Sarstedt Inc., Rommelsdorf, Germany) during each test
day. A baseline saliva sample was taken immediately
before substance administration, 1 h after the adminis-
tration of the study drug, one after in vivo exposure and at
the end of the debriefing session (see Fig. 1). After each
experimental session, samples were stored at −20 °C. For
biochemical analyses of free cortisol concentration, saliva
samples were thawed and spun at 3000 revolutions per
minute for 10 min to obtain 0.5 to 1.0 ml of clear saliva
with low viscosity. Salivary cortisol concentrations were
determined by a commercially available chemilumines-
cence immunoassay (CLIA; IBL, Hamburg, Germany).
Inter- and intra-assay coefficients of variation were both
below 8%.
Diagnostic assessment
All patients were diagnosed and screened for medical
conditions at residential treatment admission from a
psychiatrist in charge of the clinic Südhang. The patients’
characteristics and severity of alcohol dependence were
assessed with the act-info (addiction, care, and therapy
information: a nationwide documentation system for cli-
ents of Swiss drug and addiction help centers32, interview
that includes questions on socio-demographic character-
istics, such as age, gender, and employment; indices and
severity of substance use and its consequences; the
number of previous detoxifications; and psychological and
social functioning. This interview is a nationwide instru-
ment used during attendance and discharge of any inpa-
tient treatment program for addictive disorders.
The Alcohol Use Disorders Identification Test (AUDIT)
as part of the act-info assessment was used to assess the
severity of drinking problems33.
Furthermore, the following questionnaires are assessed:
Brief Symptom Check List (BSCL34); Alcohol abstinence
Self-efficacy (AASE-G35); Beck Depression Inventory
(BDI-II36).
Self-report measures during test day 1 and 2
Craving (primary outcome): Acute subjective craving as
reaction to the pictures and alcohol cues were repeatedly
measured using visual analog scales (VAS) ranging from 0
(lowest level) to 10 (highest level). Craving was further
measured using the self-rating Alcohol Urge Ques-
tionnaire (AUQ37) and the Obsessive Compulsive
Drinking Scale (OCDS38).
Stress: acute stress as reaction to the pictures and
alcohol cues were repeatedly measured using visual ana-
log scales (VAS) ranging from 0 (lowest level) to 10
(highest level).
Fig. 1 Course of study. The x-axis illustrates the time line of each test day. The test days were 1 week apart from each other and took place between
week 6 and 8 of the abstinent-oriented inpatient treatment program for AUD. In this double-blind cross-over design, patients randomly received
either cortisol or placebo at each test day (0 min). Visual analog scales for craving and stress and saliva samples were repeatedly measured. Note: Test
battery I consisted of questionnaires (AASE; OCDS; AUQ), breathalyzer test, pregnancy test, heart rate monitor; Test battery II consisted of
questionnaires about treatment credibility, side effects, and a debriefing.
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State anxiety: state anxiety was measured before sub-
stance administration using the German version39 of the
Spielberger State Anxiety Inventory (STAI-state)40, which
measures subjective anxiety at the moment of assessment.
Treatment credibility and possible side effects: patients
were asked after each treatment session whether they
believed they were assigned to active medication or pla-
cebo. Furthermore, they were asked to report any psy-
chological or physiological side effects of the study drug
after each exposure session. None of the patients reported
adverse side effects due to drug administration, nor was
there any group difference in the patients’ beliefs in
having received the active medication or placebo at test
day 1 and 2 (P ≥ 0.277).
Statistical analysis
Data were entered by blinded research assistants into
SPSS version 24.0 statistical software package. Group dif-
ferences in demographic and clinical characteristics, and
state anxiety before exposure sessions were analyzed with
unpaired t-tests and the visual analog scale craving with
Mann–Withney U test, as they were not normally dis-
tributed. The variables of interest (VAS craving, VAS stress,
OCDS, cortisol) were repeatedly measured (see Fig. 1) over
each testing day and analyzed with multivariate repeated-
measures ANOVA. Dependent variables were the mea-
surements of the variables of interest and independent
variables were the study medication (placebo or cortisol)
and treatment order (T1 Placebo/T2 Cortisol vs. T1 Cor-
tisol/T2 Placebo). The number of previous detoxifications is
a strong predictor for relapse after residential treatment and
reflects the severity of the disorder4,5. Thus, according to
the number of previous detoxification, an additional group
variable for the severity of AUD was built (1 previous
detoxification (N= 21) compared to 2 and more previous
detoxifications (N= 25)). Partial correlations were calcu-
lated for the associations between craving, stress, and
cortisol.
The areas under the curve (AUC) were calculated with
the trapezoid formula, aggregating the five measurements
of the cortisol saliva samples41. AUC G, area under curve
with respect to the ground, and AUC I, area under curve
with respect to increase were calculated. Treatment
credibility was analyzed with X2 tests. All tests were two-
tailed and a probability of <0.05 was considered statisti-
cally significant.
Results
Effects of study medication on salivary cortisol levels
There was a significant main effect of study medication
(cortisol/placebo) on salivary cortisol levels, with significant
higher cortisol levels under cortisol treatment at the four-
time points (60, 80, 100, 120min) after substance admin-
istration compared to placebo treatment (F2.3, 102.5= 19.09;
P < 0.001; Supplementary Figure S1). There was no differ-
ence in the cortisol level before substance administration at
each test day (t45= 0.151; P= 0.881).
Possible group effects according to the treatment order
and AUD severity
The patients were randomly assigned to either receive
first placebo then cortisol (T1 Placebo/T2 Cortisol: N=
23; 5 female) or first cortisol and at the second test day
cortisol (T1 Cortisol/T2Placebo: N= 23; 7 female). The
two groups did not differ regarding any demographic,
clinical nor baseline measurements at test day 1 (Table 1).
Neither did the two groups regarding AUD severity (1
previous detoxification vs. 2 and more previous detox-
ifications) differ regarding any demographic, clinical nor
baseline measurements at test day 1, except for the
number of previous detoxifications (Supplementary Table
S1).
Effects of cortisol on craving
For the primary outcome craving, as quantified by
VAS, there was a significant interaction effect between
craving, medication (Placebo vs. Cortisol), and treatment
order (T1:Placebo/T2:Cortisol vs. T1:Cortisol/T2:Pla-
cebo) (F2.5, 109.4= 6.494; P= 0.001) (Fig. 2A). Subsequent
analysis showed that subjective craving significantly
increased during in vivo exposure on test day 1 and 2
(F1.5, 109.4= 14.497; P < 0.001). Independent of the medi-
cation and treatment order, there was a significant
reduction in subjective craving from test day 1 to test day
2 (F1, 44= 11.01; P= 0.002). However, there was no sig-
nificant effect of medication (F1.0, 44.0= 0.17; P= 0.681)
nor treatment order (F1.0, 44.0= 0.12; P= 0.730) on sub-
jective craving (see Fig. 2A).
Subsequent repeated-measures ANOVA with the
additional group variable of AUD severity showed a sig-
nificant interaction effect between craving, medication
(Placebo vs. Cortisol), treatment order (T1:Placebo/T2:
Cortisol vs. T1:Cortisol/T2:Placebo), and AUD severity
(1 previous detoxification vs. 2+ previous detoxifications)
(F2.5, 107.1= 3.90; P= 0.015). Subsequent analysis for the
AUD severity groups at test day 1 and 2, showed that
patients with only one previous detoxification receiving
cortisol in the first exposure session showed an increase in
subjective craving during exposure (F2.3, 38.0= 3.23; P=
0.044; T1 VAS 6: U= 31.5, p= 0.093; All other VAS
craving at T1 and T2: p > 0.05) (Fig. 2C), while the
opposite effect was shown in patients with two or more
previous detoxifications receiving cortisol, showing a less
craving (F1.7, 38.0= 3.25; P= 0.058; T1 VAS 6: U= 42.5,
p= 0.048; T1 VAS 7: U= 41.0, p= 0.042; All other VAS
craving at T1 and T2: p > 0.05) (Fig. 2D). There was no
effect of substance administration on craving during
the second test day in both groups (all P > 0.344).
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Independent of the time of cortisol administration, both
groups showed a reduction in subjective craving from the
first to the second test day (Group 1 detox: F1, 20= 4.470;
P= 0.047; Group 2+detox: F1, 24= 7.930; P= 0.010).
Effects of cortisol on stress
The results of the two factorial analysis of variance with
repeated measurements for the visual analog scale stress, as
quantified by VAS stress showed a significant effect on stress
over the course of the two test days (F2.6, 112.1= 7.63; P <
0.001), a significant interaction between medication and
treatment order (F1.0, 43.0= 14.42; P < 0.001) and an inter-
action between stress, medication and treatment order
(F2.6, 110.49= 2.89; P= 0.046) (Figure S2). Subsequent ana-
lysis showed that subjective stress changed over the course of
the experiment at test day 1 and 2 (all p < 0.001) with a
significant reduction from test day 1 to test day 2 (F1.0, 45.0=
13.3; P= 0.001). Subsequent paired T-tests showed a sig-
nificant reduction in subjective stress from the first to the
second test day, but only during the in vivo exposure to
alcohol pictures and the preferred alcoholic drink (all
p < 0.005). Again, there was no effect of the substance
administration (F1.0, 44.0= 0.30; P= 0.586) nor treatment
order (F2.3, 101.5= 0.61; P= 0.569) on subjective stress.
Association between craving, stress, and cortisol
Subjective changes in craving (delta craving) and stress
(delta stress) within the exposure session was positively
correlated with the change in cortisol levels (AUC G
cortisol) only during the session when patients received
placebo (Craving: Placebo condition: AUC G: r= 0.343;
P= 0.019; Cortisol condition: AUC G: r=−0.070; P=
0.642; Stress: Placebo condition: AUC G: r= 0.518; P <
0.001; Cortisol condition: AUC G: r=−0.019; P= 0.901).
Additional stepwise regression analysis revealed that only
stress was a significant predictor for the endogenous
cortisol secretion (AUC G during Placebo condition)
while craving, treatment order, and severity of AUD were
not significantly associated (Table 2).
There was a significant reduction in obsessive-
compulsive drinking scale (OCDS) between the first and
the second exposure session (F1.0, 44= 19.41; P < 0.001),
Fig. 2 Effects of cortisol administration on craving during in vivo exposure to alcohol in patients with AUD. A Cortisol did not reduce craving
during in vivo exposure, but repeated exposure reduced craving from T1 to T2 independent of cortisol administration. B Patients with a history of
only one previous detoxification reported less craving during both exposure sessions compared to patients with 2 or more previous detoxifications.
C Patients with only 1 previous detoxification receiving cortisol in the first exposure session reported significantly more craving compared to the
placebo group. D Patients with 2 or more previous detoxification receiving cortisol in the first exposure session reported less craving compared to
the placebo group. Values are depicted as mean ± SD. Note: EXPO: in vivo exposure to alcohol; T1: Exposure session 1; T2: Exposure session 2; VASC:
Visual Analog Scale Craving; 1 Detox: Patient group with one previous detoxification; 2+ Detox: Patient group with two or more previous
detoxifications; Placebo-Cortisol: Patient group receiving placebo at T1 and cortisol at T2; Cortisol-Placebo: Patient group receiving cortisol at T1 and
placebo at T2. *P < 0.1; **P < 0.05.
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which was independent of the time when the patients
received cortisol or placebo (F1.0, 44= 0.55; P= 0.461).
Discussion
This study aimed to investigate the effects of a single
oral administration of cortisol on craving in patients with
AUD during repeated in vivo exposure to alcohol.
Cortisol administration had distinct effects on craving
depending on the severity of AUD and test day. While
cortisol significantly enhanced craving during exposure on
the first test day in patients with only one previous detox-
ification, it reduced craving in patients with two or more
previous detoxifications. Findings from animal and human
studies point out the crucial role of memory processes for
the development and maintenance of addiction11,42. In AUD,
the retrieval of alcohol-associated memory triggers crav-
ing6,43,44. Thus, the severity of AUD is often reflected by the
level of craving and associated relapses5,45,46. During expo-
sure to alcohol cues, patients with more than two previous
detoxifications reported more craving that might result from
more or stronger alcohol-associated memories that are
readily retrieved and elicit craving. In these patients, the
administration of cortisol might have inhibited the retrieval
of alcohol-associated memories during in vivo exposure and
thus reduced craving. On the other side, we found the
opposite effect of cortisol administration on craving in
patients with only one previous detoxification. Even though
there is extensive evidence that stress increases alcohol
craving and the vulnerability for relapse47–51, findings from
animal and human studies are heterogeneous regarding the
involvement of cortisol in mediating these stress effects52–54.
Another explanation for the differential effects may come
from the adaptation in the hypothalamic–pituitary–adrenal
(HPA) axis function through chronic alcohol use and
AUD47,55–58. Thus, it might be possible that changes in the
HPA axis depend on the severity of AUD and therefore lead
to differential responses to external glucocorticoids. How-
ever, this would have to be tested with HPA-reactivity tests,
such as the dexamethasone suppression test, in these patient
groups. However, the distinct effect of cortisol on craving
cannot be conclusively explained. Thus, more studies are
needed to elucidate the underlying mechanism and the usage
of cortisol as an add-on treatment for AUD needs to be
further investigated with regard to AUD severity.
Independent of substance administration, repeated in vivo
exposure reduced craving and stress from test day 1 to test
day 2. These findings have several implications. First, the
significant increase of craving and stress following in vivo
exposure evidenced that after repeated alcohol administra-
tion, cues associated with the consumption of alcohol (such
as the sight or smell of alcohol) can elicit conditioned
responses (for reviews, see refs. 59,60). Furthermore, the
intensity of the response is positively related to the subject’s
degree of dependence61. This underlines that with ongoing
alcohol use the associated memories become stronger and
particularly difficult to disrupt. Second, exposure to such cues
in the absence of alcohol ingestion, can lead to the formation
of a new “extinction” memory, which is supported by our
findings that only one standardized in vivo exposure sessions
significantly reduced craving and stress, which in turn might
reduce the probability of relapse to alcohol drinking59,62.
In vivo exposure to the preferred alcoholic drink sig-
nificantly increased craving and stress but not salivary cor-
tisol during both exposure sessions in the placebo condition.
Chronic alcohol use and AUD is associated with adaptations
in stress-related brain pathways and the HPA-axis function
as well as in the autonomic arousal and reward (mesolimbic
dopamine) pathways47,55–58. Acute alcohol administration
has been shown to enhance levels of HPA-axis hormones
(e.g., cortisol) in humans and animal models (for review, see
ref. 63). As dependence on alcohol develops, HPA-axis
activity appears to become dysregulated, and ongoing
chronic exposure to alcohol may lead to a reduction in the
responsiveness of the HPA axis to external stimuli64,65.
While the acute and chronic alcohol intoxication and
withdrawal robustly increase cortisol secretion66,67, a sup-
pression of the HPA axis responsiveness with low basal levels
of cortisol68 and a blunted cortisol responses to social stress
tasks69 and alcohol cue exposure70,71 is reported in early
abstinent patients with AUD. Higher cortisol response to
stress appears to have protective effects and enables indivi-
duals to reduce or regulate negative affect14,72. This imbal-
ance between the psychological and physiological stress
response is in line with our findings, as patients reported a
significant increase in craving and stress during exposure to
alcohol while they showed a blunted cortisol response, which
might reflect the potential impairment of the person’s ability
to adequately cope with relapse-inducing stressors. However,
the findings on cortisol reactivity to alcohol cue exposure are
heterogeneous69,73, suggesting a dysfunctional HPA system
rather than specific cortisol hypo-responsivity in AUD74,
depending on the different stages of AUD such as heavy
drinking, withdrawal, early abstinence, prolonged abstinence,
and relapse71. As HPA response to stress significantly
Table 2 Stepwise regression with cortisol as the dependent variable, and cortisol, stress, treatment order, and severity
of AUD as predictors of interest.
R² Corrected R² ΔR² ΔF df ΔP Standardized ß t P
Stress Δ 0.268 0.251 0.268 15.74 1;43 0.000 0.518 3.97 0.000
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influences and modulates the affective and behavioral reg-
ulation, the alteration of the HPA-axis might have a potential
impact in the vulnerability to relapse in patients with AUD.
There are some limitations, that need to be addressed. The
effects of stress and cortisol on memory process depend on
various factors (e.g., cortisol reactivity, gender, population,
timing) highlighting the importance of well-elaborated
methodology18,23,24,75. As cortisol has distinct effects on
memory retrieval and consolidation, careful study designs are
warranted. The cross-over design, complicated the analysis
and led to a loss of power due to the strong habituation effect
in craving from the first to the second test day. Thus, for the
investigation of the acute effect of cortisol in craving only
short exposures to alcohol cues would have been a better
approach. Timing of glucocorticoid administration seems to
be a key determinant of its effects on memory processes18.
Thus, timing and dosage of glucocorticoid administration
was based on our previous clinical studies14,15,29,30. However,
as stated before there is evidence that patients with AUD
show altered HPA-activity and often altered markers of liver
function or liver disease according to the stage of AUD
(acute or chronic alcohol intoxication, withdrawal, early
abstinence, long-term abstinence). Thus, timing and dosage
of glucocorticoid administration may need to be adjusted in
patients with severe AUD and have to be tested in further
studies. To evaluate possible beneficial effects on the pro-
motion of cortisol administration on extinction memory,
repeated cortisol administration in combination with expo-
sure therapy and follow-up assessment should be planned.
Summarized, this is the first study to examine the acute
effects of cortisol on craving during in vivo exposure in
patients with AUD. Cortisol administration had distinct
effects on craving depending on the severity of AUD,
which highlights the need for future research investigating
HPA-axis functioning in patients with AUD more thor-
oughly. Cortisol reduced craving in patients with severe
AUD and repeated exposure reduced craving. Thus,
adding cortisol to in vivo exposure might be a promising
approach for reducing the strength of drug-associated
memories and promote the consolidation of extinction
memory in patients with severe AUD. However, the pre-
sented differential effect of cortisol administration on
craving depending on the severity of AUD is not fully
understood and highlights the need for further studies to
elucidate the underlying mechanism. The findings
underline the importance of the development of new
treatment approaches that address neurobiological chan-
ges to learning and memory systems, which play a crucial
role in the development and maintenance of addiction.
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